Patent ID: 7049344

Claim:
A method of inhibiting urokinase plasminogen activator in a human or animal patient, comprising: administering to the patient a selective urokinase plasminogen activator inhibiting effective amount of a compound of the formula (I): wherein, Ar is an aromatic or heteroaromatic ring system, X 1 is a radical of the formula (IIa), (IIb) or (IIc): R 1 is H, an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or heteroaryl radical, R 2 is halogen, C(R 3 ) 3 , C 2 (R 3 ) 5 , OC(R 3 ) 3 or OC 2 (R 3 ) 5 , R 3 is in each case independently H or halogen, R 4 and R 5 are H or an unsubstituted or substituted alkyl, alkenyl or alkynyl radical, where at least one of the radicals R 4 and R 5 contain a hydrogen bond donor group, where the hydrogen bond donor group provides a hydrogen atom or/and an electron pair for a hydrogen bond, R 6 and R 7 are H or an unsubstituted or substituted alkyl, alkenyl or alkynyl radical, where at least one of the radicals R 6 and R 7 contains a hydrogen bond donor group, where the hydrogen bond donor group provides a hydrogen atom or/and an electron pair for a hydrogen bond and where R 4 or R 5 may be bridged with R 6 or R 7 , R 8 is H or an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or heteroaryl radical or —SO 2 —R 9 , where R 8 may or may not be bridged with R 6 or R 7 , R 9 is H or an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or heteroaryl radical, X 2 is a hydrogen bond acceptor group, which is NH, NR 10 , O or S, R 10 is an unsubstituted or substituted alkyl, alkenyl or alkynyl radical, and m is an integer from 0 to 4, or a salt thereof.